PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce the appointment of Dr. Makarand (Mak) Jawadekar as the President of the Company, effective immediately. Dr. Jawadekar will also continue as the Chief Science Officer and as a director of the Company. Former President, Mr. Stephen Van Deventer, will continue to serve as Chairman and CEO of PreveCeutical.
Dr. Jawadekar previously spent 28 years working at Pfizer Inc., where he served as Director of Portfolio Management. During his Pfizer tenure, he was a bench scientist for the formulation of the blockbuster drug, Zoloft (sertraline). Dr. Jawadekar was also involved in Pfizer’s external drug delivery technology assessment function and applying unique drug delivery systems into the company’s novel products. He has extensive experience managing clinical trial supply manufacturing, scale-up and technology transfers, performance metrics evaluations and assessments, commercial drug product formulation development, contracting, outsourcing and research and development performance benchmarking.
Dr. Jawadekar has received numerous distinctions and awards. In 2006, he was invited to serve as part of President George W. Bush’s trade delegation to India. He represented Pfizer at the 2009 BioAsia International Conference, and was the recipient of the Indian Pharmaceutical Association’s 2001 M.L. Khorana Memorial Lecture of the Year Award.
Dr. Jawadekar is a member of the Board of Directors of New York-based non-profit Abilities Inc. He serves on the strategic advisory boards of numerous pharma, biotech, drug delivery technology and nutraceutical companies. Dr. Jawadekar earned his Ph.D. in Pharmaceutics from the University of Minnesota in 1982.
Mr. Stephen Van Deventer commented, “I look forward to Mak’s direction as President as we move forward with our plans to secure strategic partnerships to accelerate PreveCeutical’s innovative research and development programs to commercialization. Mak’s expertise and high-level associates in the pharmaceutical sector is of extreme value to us in the Company’s exciting next phase.”
Dr. Jawadekar commented, “I am very pleased to accept the new role of President and I hope to add further value through making selective contributions to the Company’s product portfolio beyond science and technology.”
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & CEO
For further information, please contact:
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company’s anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, pursue business partnerships, complete its research programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.